We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prostate Cancer Blood Test Found Equally Effective Across Ethnic Groups

By LabMedica International staff writers
Posted on 07 Aug 2024

Stockholm3, a prostate cancer test that analyzes a combination of protein and genetic markers from a blood sample using an algorithm, has been shown to predict the likelihood of clinically significant cancer with greater accuracy than the conventional prostate-specific antigen (PSA) test. More...

Research involving over 90,000 men indicates that Stockholm3 outperforms PSA, helping to avoid unnecessary MRIs and biopsies, and identifying serious cancers even in men with low or normal PSA levels. Historically, these studies primarily involved a predominantly White Scandinavian population, casting doubt on their applicability globally. Now, a new study has confirmed that Stockholm3 is equally effective across diverse ethnic backgrounds and continues to outperform the PSA standard significantly.

The study, conducted by researchers at Karolinska Institutet (Stockholm, Sweden) where the Stockholm3 blood test was developed, involved more than 2,000 men from 17 clinics, with ethnic backgrounds including 16% Asian, 24% African-American, 14% Latin American, and 46% White American. Each participant was recommended for a prostate biopsy based on elevated PSA scores, abnormal rectal exams, concerning MRI results, or other suspicious clinical signs. Before undergoing a biopsy, each subject had a blood sample taken for the Stockholm3 test, performed without knowledge of the biopsy outcomes.

The findings published in The Journal of Clinical Oncology showed that clinically relevant prostate cancer was detected in 29% of participants, with a slightly higher incidence among African Americans and a lower one among Asians. Importantly, the Stockholm3 test was shown to potentially reduce unnecessary biopsies by 45% (673 compared to 1,226), while maintaining effectiveness in detecting all clinically significant cases across different ethnicities. The researchers assert that these findings address critical concerns and anticipate that this evidence will facilitate broader adoption of the Stockholm3 test globally.

“The study demonstrates that the Stockholm3 test is just as effective on an ethnically mixed group as it is on a White, Swedish population,” said the study’s lead author Hari T. Vigneswaran, doctor and PhD student at Karolinska Institutet.

Related Links:
Karolinska Institutet


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.